Author

S. Ryhänen

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#protein folding Open access Oct 2026

Longitudinal Plasma Proteomics Distinguishes Primary Immune Tolerance from Chronic Graft-versus-Host Disease After Pediatric allo-HSCT

Chronic graft-versus-host disease (cGvHD) remains a major cause of morbidity after pediatric allogeneic hematopoietic stem cell transplantation (HSCT), but the early plasma molecular features associated with primary immune tolerance (PIT) versus cGvHD are incompletely understood. We performed longitudinal LC-MS plasma...

D. Kim, Y. Jing, E. Äärimaa et al. · medRxiv · 0 citations

Open access Sep 2026

Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy.

CD19-directed CAR T-cell therapy (CART19) has transformed relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) management, but the prognostic impact of immunotherapy sensitivity and post-allogeneic hematopoietic cell transplantation (alloHCT) relapse timing in real-world practice remains unclear. We re...

V. Ortíz-Maldonado, J. Galimard, Giorgio Ottaviano et al. · Blood Advances · 0 citations

Case report Open access Sep 2026

Neurofibromatosis 1 (NF1) gene testing reveals rising variant allele fraction as an early warning sign of juvenile myelomonocytic leukemia.

This case highlights the importance of genetic testing in establishing an NF1 diagnosis in young children, and an increasing variant allele fraction may signal an emerging JMML, and early testing can provide a critical time window for timely and effective treatment.

S. Peltonen, Christian Johansson, Marika H. Grönroos et al. · European Journal of Medical... · 0 citations